Consumption of lycopene-rich tomatoes improved glucose homeostasis in rats via an increase in leptin levels
AbstractThe lycopene content of tomatoes is important because of its effects on vital physiological functions such as improvement of glucose tolerance and non-alcoholic fatty liver disease. To investigate the influence of the lycopene content of tomatoes on glucose tolerance and hepatic lipid content, homogenates of lycopene-rich (LR) or lycopene-free negative control (NC) tomato varieties were administrated to normal rats for 4 weeks. At the end of the experiment, an oral glucose tolerance test (OGTT) was performed. Rats were fed once and then dissected. According to the OGTT results, plasma glucose levels in the LR group were 10% and 9% lower at 15 min and 30 min, respectively, than those in the NC group, whereas plas ma insulin levels did not differ between the groups at either time point. Upon dissection, plasma leptin levels in the LR group were higher than those in the NC group, while plasma adiponectin levels did not differ between groups. With the exception of retinol palmitate, no carotenoids were detected in the liver by HPLC analysis. Hepatic retinol palmitate levels and hepatic triacyl glyceride levels did not differ between the groups. We concluded that in normal rats, a lycopene-rich tomato variety improved glucose tolerance via an increase in plasma leptin levels that enhanced insulin sensitivi ty but did not affect carotenoid accumulation or lipid metabolism.
Publication date: Available online 11 October 2019Source: The Lancet HIVAuthor(s): Takara L Stanley, Lindsay T Fourman, Meghan N Feldpausch, Julia Purdy, Isabel Zheng, Chelsea S Pan, Julia Aepfelbacher, Colleen Buckless, Andrew Tsao, Anela Kellogg, Karen Branch, Hang Lee, Chia-Ying Liu, Kathleen E Corey, Raymond T Chung, Martin Torriani, David E Kleiner, Colleen M Hadigan, Steven K GrinspoonSummaryBackgroundNon-alcoholic fatty liver disease (NAFLD) is a substantial cause of comorbidity in people with HIV and there are no proven pharmacological treatments for the disease in this population. We assessed the effects of tesamo...
This study aimed to investigate prevalence and risk factors of biopsy proven NAFLD in a cluster of healthy non-obese and lean individuals.Methods and MaterialsIn a retrospective study, adult (> 18 years) apparently healthy individuals who had donated liver to pediatric patients between July 2012 and October 2018 were included. Non-obese and lean individuals were defined as BMI
Authors: Carrier P, Debette-Gratien M, Jacques J, Loustaud-Ratti V Abstract The global population is aging, and so the number of older cirrhotic patients is increasing. Older patients are characterised by a risk of frailty and comorbidities, and age is a risk factor for mortality in cirrhotic patients. The incidence of non-alcoholic fatty liver disease as an aetiology of cirrhosis is increasing, while that of chronic viral hepatitis is decreasing. Also, cirrhosis is frequently idiopathic. The management of portal hypertension in older cirrhotic patients is similar to that in younger patients, despite the greater ri...
CONCLUSIONS: Our study showed that the upregulation of NLRP3 inflammasome activated by cardiolipin is crucial in NASH pathogenesis, which might provide a novel potential role of cardiolipin blockade in the treatment of NASH. PMID: 31599445 [PubMed - in process]
Histopathological assessments play an important role in the diagnosis and management of patients with liver disease. For some conditions, liver biopsy is still routinely used to establish the cause of liver disease. In other circumstances, evaluation of morphological changes provides additional information that is useful for clinical management, for example when assessing disease severity in chronic viral hepatitis and non-alcoholic fatty liver disease. However, with the increased use of non-invasive methods for assessing the severity of liver injury, particularly fibrosis, the role of liver biopsy in this respect is changing.
Liver lipid accumulation induced by high-fat diet (HFD) is an early onset process of non-alcoholic fatty liver diseases (NAFLD). Protein kinase A (PKA) is known to be involved in hepatic lipid metabolism. Howe...
Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disorder. NAFLD, associated lipotoxicity, fibrosis, oxidative stress, and altered mitochondrial metabolism, is responsible for systemic inflammation, which contributes to organ dysfunction in extrahepatic tissues, including the heart.We investigated the ability of L-carnitine (LC) to oppose the pathogenic mechanisms underlying NAFLD progression and associated heart dysfunction, in a mouse model of methionine-choline-deficient diet (MCDD).
We report a case of a post RYGB patient with severe malnutrition who developed non-alcoholic fatty liver disease. Severe chronic malnutrition predisposed by bariatric surgery is considered as potential mechanism of hepatic steatosis. Liver function should be routinely monitored for post bariatric patients with nutritional risk. Proper enteral and parenteral nutrition support can be a major treatment for hepatic steatosis induced by severe malnutrition.
Hepatocellular carcinoma (HCC) and cholangiocarcinoma are the two major types of primary liver tumour. Both are increasing in incidence in the UK, in the case of HCC because of the increasing prevalence of chronic liver disease, particularly caused by alcohol and non-alcoholic fatty liver disease. They have a poor overall prognosis because of late presentation and the presence of underlying liver cirrhosis in patients with HCC. Patients usually present with a liver mass or jaundice. Assessment is primarily radiological by means of computed tomography and/or magnetic resonance imaging.